Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Go back to Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

February 28, 2023 4:24 PM EST

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

... More